Abstract 1877
Background
Based on mRNA expression, accRCC can be divided in four molecular subtypes (ccrcc1-4), associated with prognosis, angiogenic signature, immune phenotype and therapy response. miRNAs are master regulators of mRNA function. We assessed the correlation of miRNA expression with (1) ccrccc1-4 subtypes, (2) mRNA targets and (3) outcome.
Methods
We performed miRNome analysis of 128 accRCC. (1) Unsupervised hierarchical clustering was done using 50 miRNAs with the most variable expression across all samples. Results were validated on TCGA data (n = 255). (2) For miRNAs with subtype-specific expression, we performed pathway analysis of predicted mRNA targets (IPA, KEGG) and assessed target-downregulation in TCGA. (3) We used Cox regression to correlate miRNA expression with overall survival (OS) since diagnosis. Hazard ratios (HR) were correlated with subtype-specific expression (Pearson).
Results
(1) Samples separated in two miRNA clusters, that partially overlapped with molecular subtypes. Cluster 1 consisted of 69% favourable subtypes (ccrcc2 or 3), cluster 2 of 77% unfavourable (ccrcc1 or 4) (p < 2.2e-16). (2) Pathway analysis of predicted mRNA targets and targets suppressed in TCGA, suggested that favourable subtypes exhibit more angiogenic signaling, whereas unfavourable subtypes activate pathways involved in tumor invasiveness. (3) Several miRNAs were significantly associated with OS. There was a robust correlation in the entire dataset between HR for OS and differential expression between favourable/unfavourable subtypes (r = 0.322; p < 0.0001).Table:
973P
miRNA | Subtype-specific expression log2FoldChange <0: higher in ccrcc1 or -4 (unfavourable) log2FoldChange >0: higher in ccrcc2 or -3 (favourable) | *p<0.05 ** false discovery rate <0.05 | Overall survival (hazard ratio) | |
---|---|---|---|---|
182-5p | -1,43 | ** | 1,25 | ** |
3529-3p | -1,42 | ** | 1,37 | ** |
335-3p | -1,33 | ** | 1,25 | ** |
34c-5p | -1,22 | ** | 1,25 | ** |
193b-3p | -1,17 | ** | 1,31 | ** |
370-3p | -1,07 | ** | 1,16 | ** |
199b-5p | -1,05 | ** | 1,26 | ** |
21-3p | -0,89 | ** | 1,47 | ** |
574-5p | -0,89 | ** | 1,40 | ** |
4792 | -0,88 | ** | 0,88 | * |
let-7i-5p | -0,81 | ** | 1,66 | ** |
652-3p | -0,75 | ** | 1,39 | ** |
1301-3p | -0,70 | ** | 1,39 | ** |
222-3p | -0,66 | ** | 1,31 | * |
320a | -0,63 | ** | 1,28 | ** |
425-5p | -0,62 | ** | 1,66 | ** |
149-5p | -0,61 | ** | 1,32 | * |
146b-5p | -0,54 | * | 1,49 | ** |
193b-5p | -0,49 | 1,21 | ** | |
185-5p | -0,49 | ** | 1,42 | ** |
21-5p | -0,42 | * | 1,68 | ** |
7641 | -0,33 | 0,80 | ** | |
320b | -0,28 | 1,25 | ** | |
1260b | -0,15 | 0,79 | ** | |
4454 | 0,15 | 0,80 | ** | |
6880-5p | 0,25 | 0,64 | ** | |
27b-3p | 0,36 | ** | 0,71 | * |
1260a | 0,38 | 0,73 | ** | |
7977 | 0,39 | 0,73 | ** | |
23b-3p | 0,48 | ** | 0,81 | ** |
2392 | 0,55 | 0,80 | ** | |
194-5p | 0,55 | * | 0,74 | ** |
30c-5p | 0,70 | ** | 0,78 | * |
190a-5p | 0,86 | ** | 0,83 | ** |
204-5p | 1,23 | ** | 0,71 | ** |
135a-5p | 1,37 | ** | 0,86 | ** |
Conclusions
accRCC molecular subtypes exhibit different miRNA expression patterns. Differentially expressed miRNAs are implicated in pathways driving tumor biology and strongly correlated with OS. These findings underscore the robustness of the molecular subtypes and are, to the best of our knowledge, the first to show an association of global miRNome expression with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fonds Wetenschappelijk Onderzoek Vlaanderen.
Disclosure
M. Albersen: Research grant / Funding (self): Ipsen. B. Beuselinck: Advisory / Consultancy, Research grant / Funding (self): Bristol Meyers Squibb; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract
2655 - The K-BASKET trial: A prospective phase II biomarker-driven multiple basket trial in Korean solid cancer patients.
Presenter: Seul Kim
Session: Poster Display session 3
Resources:
Abstract
5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?
Presenter: Constanza Linossi
Session: Poster Display session 3
Resources:
Abstract
3799 - Validation of a tumour mutational burden workflow on routine histological samples of colorectal cancer and assessment of a cohort with synchronous hepatic metastases
Presenter: Andrea Mafficini
Session: Poster Display session 3
Resources:
Abstract
4647 - Microsatellite Instability Testing and Lynch Syndrome Screening For Colorectal Cancer Patients Through Tumor Sequencing
Presenter: Li Liu
Session: Poster Display session 3
Resources:
Abstract
3231 - "Liquid Withdarw" technique in CT-guided cutting needle lung biopsy: decreased incidence of complications and increased tissue amount for lung cancer molecular testing.
Presenter: Xue Wang
Session: Poster Display session 3
Resources:
Abstract
3282 - WGS Implementation in standard cancer Diagnostics for Every cancer patient (WIDE)
Presenter: Paul Roepman
Session: Poster Display session 3
Resources:
Abstract
5905 - Known and unknown gene fusion detection capabilities of solid tumor laboratories conducting next generation sequencing in 6 countries
Presenter: Steph Finucane
Session: Poster Display session 3
Resources:
Abstract
4238 - Clinical and Analytical Accuracy of a 523 Gene Panel Next-Generation Sequencing (NGS) Assay on Formalin-Fixed Paraffin-Embedded (FFPE) Solid Tumor Samples
Presenter: Ina Deras
Session: Poster Display session 3
Resources:
Abstract
2493 - Methylation analysis of MLH1 using droplet digital PCR and methylation sensitive restriction enzyme.
Presenter: Celine De Rop
Session: Poster Display session 3
Resources:
Abstract